A simple quantitative model for the prediction of exposure of renally excreted drugs in pregnant women: a comparison with whole body PBPK model

Abstract

Aim: The objective of this study was to develop a simple quantitative model (SQM) to predict maximum plasma concentration (C_max) and the area under the curve (AUC) of renally excreted drugs (n = 16) in pregnant women from non-pregnant women.

Methods: The SQM was developed using 6 physiological parameters and the fraction unbound protein in plasma (f_up) as the product characteristic. The six physiological parameters used in this study were total body water, blood volume, cardiac output, glomerular filtration rate (GFR), volume of the fetoplacental unit and blood flow of the fetoplacental unit. A factor was derived based on the average values of the physiological parameters and f_up for different gestational ages to predict C_max and AUC values in pregnant women from non-pregnant women. The predicted values from SQM were then compared with the dedicated clinical studies as well as predicted values by a physiologically-based pharmacokinetic (PBPK) model.

Results: Out of 17 C_max data points, 15 (88.2%), 15 (88.2%), and 12 (70.6%) data points were within 0.5–2.0-fold, 0.5–1.5-fold and 0.7–1.30-fold prediction error, respectively, by SQM, whereas, 17 (100%), 15 (88.2%), and 13 (76.5%) data points were within 0.5–2.0-fold, 0.5–1.5-fold and 0.7–1.30 fold prediction error, respectively, by PBPK. Out of 36 AUC data points, 36 (100%), 34 (94.4%), and 30 (83.3%) data points were within 0.5–2.0-fold, 0.5–1.5-fold and 0.7–1.30-fold prediction error, respectively, by SQM, whereas, 35 (97.2%), 33 (91.7%), and 27 (75%) data points were within 0.5–2.0-fold, 0.5–1.5-fold and 0.7–1.30-fold prediction error, respectively, by PBPK. The results of the study indicated that the predictive power of both models was very good.

Conclusions: The results of the study indicate that the SQM in its predictive performance is as robust and accurate as whole body PBPK.

Keywords

Pregnancy / simple quantitative model / whole body PBPK / Cmax and AUC / renally excreted drugs

References

[1] Tegenge MA, Mahmood I, Struble EB, Sauna Z. Pharmacokinetics of antibodies during pregnancy: General pharmacokinetics and pregnancy related physiological changes (Part 1). Int Immunopharmacol. 2023; 117: 109914.

[2] Costantine MM. Physiologic and pharmacokinetic changes in pregnancy. Front Pharmacol. 2014; 5: 65.

[3] Muñoz Z. Physiology of pregnancy [Internet]. [cited 2024 Jul]. Available from: www.merckmanuals.com

[4] Sanghavi M, Rutherford JD. Cardiovascular physiology of pregnancy. Circulation. 2014; 130: 1003—8.

[5] Moya J, Phillips L, Sanford J, Wooton M, Gregg A, Schuda L. A review of physiological and behavioral changes during pregnancy and lactation: potential exposure factors and data gaps. J Expo Sci Environ Epidemiol. 2014; 24: 449-58.

[6] Cheung KL, Lafayette RA. Renal physiology of pregnancy. Adv Chronic Kidney Dis. 2013; 20: 209—14.

[7] Abduljalil K, Furness P, Johnson TN, Rostami—Hodjegan A, Soltani H. Anatomical, physiological and metabolic changes with gestational age during normal pregnancy: a database for parameters required in physiologically based pharmacokinetic modelling. Clin Pharmacokinet. 2012; 51: 365-96.

[8] Allegaert K, Quinney SK, Dallmann A. Physiologically Based Pharmacokinetic Modeling in Pregnancy, during Lactation and in Neonates: Achievements, Challenges and Future Directions. Pharmaceutics. 2024; 16: 500.

[9] Thepaut E, Brochot C, Chardon K, Persone S, Zeman F. Pregnancy—PBPK models: How are biochemical and physiological processes integrated? Comput Toxicol. 2023; 27: 100282.

[10] Björkman S. Reduction and lumping of physiologically based pharmacokinetic models: prediction of the disposition of fentanyl and pethidine in humans by successively simplified models. J Pharmacokinet Pharmacodyn. 2003; 30: 285-307.

[11] Cao Y, Jusko WJ. Applications of minimal physiologically—based pharmacokinetic models. J Pharmacokinet Pharmacodyn. 2012; 39: 711—23.

[12] Cao Y, Balthasar JP, Jusko WJ. Second—generation minimal physiologically—based pharmacokinetic model for monoclonal antibodies. J Pharmacokinet Pharmacodyn. 2013; 40: 597-607.

[13] Zhao J, Cao Y, Jusko WJ. Across—Species Scaling of Monoclonal Antibody Pharmacokinetics Using a Minimal PBPK Model. Pharm Res. 2015; 32: 3269-81.

[14] Mahmood I. A GFR—Based Method to Predict the Effect of Renal Impairment on the Exposure or Clearance of Renally Excreted Drugs: A Comparative Study Between a Simple GFR Method and a Physiologically Based Pharmacokinetic Model. Drugs R D. 2020; 20: 377-87.

[15] Mahmood I. Prediction of drug exposure in hepatic impairment: a comparison between minimal physiologically based pharmacokinetic (mPBPK) and whole body PBPK models. Explor Drug Sci. 2025; 3: 100894.

[16] Xia B, Heimbach T, Gollen R, Nanavati C, He H. A simplified PBPK modeling approach for prediction of pharmacokinetics of four primarily renally excreted and CYP3A metabolized compounds during pregnancy. AAPS J. 2013; 15: 1012-24.

[17] Song L, Yu Z, Xu Y, Li X, Liu X, Liu D, et al. Preliminary physiologically based pharmacokinetic modeling of renally cleared drugs in Chinese pregnant women. Biopharm Drug Dispos. 2020; 41: 248-67.

[18] Abduljalil K, Pansari A, Ning J, Jamei M. Prediction of Maternal and Fetal Acyclovir, Emtricitabine, Lamivudine, and Metformin Concentrations during Pregnancy Using a Physiologically Based Pharmacokinetic Modeling Approach. Clin Pharmacokinet. 2022; 61: 725—48.

[19] Dallmann A, Ince I, Solodenko J, Meyer M, Willmann S, Eissing T, et al. Physiologically Based Pharmacokinetic Modeling of Renally Cleared Drugs in Pregnant Women. Clin Pharmacokinet. 2017; 56: 1525-41.

[20] Coppola P, Kerwash E, Cole S. The Use of Pregnancy Physiologically Based Pharmacokinetic Modeling for Renally Cleared Drugs. J Clin Pharmacol. 2022; 62 Suppl 1: S129-39.

[21] Pillai VC, Han K, Beigi RH, Hankins GD, Clark S, Hebert MF, et al. Population pharmacokinetics of oseltamivir in non—pregnant and pregnant women. Br J Clin Pharmacol. 2015; 80: 1042—50.

[22] De Sousa Mendes M, Hirt D, Urien S, Valade E, Bouazza N, Foissac F, et al. Physiologically—based pharmacokinetic modeling of renally excreted antiretroviral drugs in pregnant women. Br J Clin Pharmacol. 2015; 80: 1031-41.

[23] Colbers APH, Hawkins DA, Gingelmaier A, Kabeya K, Rockstroh JK, Wyen C, et al. The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV—1—infected pregnant women. AIDS. 2013; 27: 739-48.

[24] Tegenge MA, Mahmood I, Struble EB, Sauna Z. Pharmacokinetics of antibodies during Pregnancy: Impact of pregnancy on the pharmacokinetics of antibodies (Part 2). Int Immunopharmacol. 2023; 119: 109915.

[25] Mahmood I, Li Z. Immunoglobulin therapies for primary immunodeficiency diseases (part 1): understanding the pharmacokinetics. Immunotherapy. 2024; 16: 879-94.

[26] DrugBank [Internet]. [cited 2024 Jul]. Available from: https://go.drugbank.com/